Literature DB >> 21196223

Regulation of MDM4.

Michael P Markey1.   

Abstract

Mouse double minute 4 (MDM4), also known as MDMX or HDMX (human MDMX), is a critical negative regulator of the tumor suppressor p53. Under normal growth conditions, MDM4 contributes to the repression of p53 activity. Upon DNA damage, it becomes important to down-regulate MDM4 to allow a full p53 response. Here, the mechanisms by which MDM4 activity is controlled are reviewed and discussed, starting with alterations in copy number, then control of transcription, mRNA stability, translation, and finally post-translational interactions, modifications, localization, and targeting by recently developed drugs.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21196223     DOI: 10.2741/3780

Source DB:  PubMed          Journal:  Front Biosci (Landmark Ed)        ISSN: 2768-6698


  12 in total

1.  Calpain-mediated degradation of MDMx/MDM4 contributes to HIV-induced neuronal damage.

Authors:  Daniel J Colacurcio; Alyssa Yeager; Dennis L Kolson; Kelly L Jordan-Sciutto; Cagla Akay
Journal:  Mol Cell Neurosci       Date:  2013-10-12       Impact factor: 4.314

2.  Copy Number Aberrations of Multiple Genes Identified as Prognostic Markers for Extrahepatic Metastasis-free Survival of Patients with Hepatocellular Carcinoma.

Authors:  Zhong-Zheng Zhu; Ling-Ling Bao; Kun Zhao; Qing Xu; Jia-Yi Zhu; Ke-Xuan Zhu; Bing-Ji Wen; Ying-Quan Ye; Xiao-Xi Wan; Liang-Liang Wang; Song-Qin He; Wen-Ming Cong
Journal:  Curr Med Sci       Date:  2019-10-14

3.  Role of an MDM4 polymorphism in the early age of onset of nasopharyngeal carcinoma.

Authors:  Yao Wei Zhang; Jian Guan; Yong Zhang; Yu Rong Qiu; Long Hua Chen
Journal:  Oncol Lett       Date:  2012-03-02       Impact factor: 2.967

4.  MDMX is a prognostic factor for non-small cell lung cancer and regulates its sensitivity to cisplatin.

Authors:  Han Zhao; Yu-Zhuo Xie; Rui Xing; Ming Sun; Feng Chi; Yue-Can Zeng
Journal:  Cell Oncol (Dordr)       Date:  2017-05-31       Impact factor: 6.730

Review 5.  The Roles of MDM2 and MDMX in Cancer.

Authors:  Orit Karni-Schmidt; Maria Lokshin; Carol Prives
Journal:  Annu Rev Pathol       Date:  2016-03-17       Impact factor: 23.472

Review 6.  Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.

Authors:  Qin Li; Guillermina Lozano
Journal:  Clin Cancer Res       Date:  2012-12-21       Impact factor: 12.531

7.  MicroRNA-34a modulates MDM4 expression via a target site in the open reading frame.

Authors:  Pooja Mandke; Nicholas Wyatt; Jillian Fraser; Benjamin Bates; Steven J Berberich; Michael P Markey
Journal:  PLoS One       Date:  2012-08-01       Impact factor: 3.240

Review 8.  MicroRNA binding site polymorphisms as biomarkers in cancer management and research.

Authors:  Monica Cipollini; Stefano Landi; Federica Gemignani
Journal:  Pharmgenomics Pers Med       Date:  2014-07-23

Review 9.  MDM2/X Inhibitors as Radiosensitizers for Glioblastoma Targeted Therapy.

Authors:  Xanthene Miles; Charlot Vandevoorde; Alistair Hunter; Julie Bolcaen
Journal:  Front Oncol       Date:  2021-07-08       Impact factor: 6.244

10.  Whole genome sequence analysis links chromothripsis to EGFR, MDM2, MDM4, and CDK4 amplification in glioblastoma.

Authors:  John M Furgason; Robert F Koncar; Sharon K Michelhaugh; Fazlul H Sarkar; Sandeep Mittal; Andrew E Sloan; Jill S Barnholtz-Sloan; El Mustapha Bahassi
Journal:  Oncoscience       Date:  2015-07-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.